Exome Asset Management LLC Purchases 25,600 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Exome Asset Management LLC raised its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) by 20.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 149,600 shares of the company’s stock after buying an additional 25,600 shares during the period. Exome Asset Management LLC’s holdings in Pliant Therapeutics were worth $1,677,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Rice Hall James & Associates LLC purchased a new stake in shares of Pliant Therapeutics during the second quarter valued at approximately $1,372,000. Renaissance Technologies LLC grew its stake in Pliant Therapeutics by 233.8% in the 2nd quarter. Renaissance Technologies LLC now owns 253,369 shares of the company’s stock valued at $2,724,000 after purchasing an additional 177,469 shares during the period. Candriam S.C.A. increased its position in shares of Pliant Therapeutics by 52.0% during the 2nd quarter. Candriam S.C.A. now owns 833,216 shares of the company’s stock valued at $8,957,000 after purchasing an additional 285,216 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Pliant Therapeutics by 1.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 83,483 shares of the company’s stock valued at $897,000 after purchasing an additional 1,191 shares during the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in shares of Pliant Therapeutics by 233.8% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 91,979 shares of the company’s stock worth $1,031,000 after buying an additional 64,422 shares during the last quarter. Institutional investors own 97.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of Pliant Therapeutics in a report on Friday, November 8th. Leerink Partnrs raised shares of Pliant Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Leerink Partners assumed coverage on shares of Pliant Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $33.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $40.50.

Pliant Therapeutics Price Performance

Shares of NASDAQ:PLRX opened at $13.30 on Friday. The firm has a market capitalization of $809.36 million, a PE ratio of -3.98 and a beta of 1.05. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $13.88 and a two-hundred day moving average price of $12.77. Pliant Therapeutics, Inc. has a twelve month low of $10.22 and a twelve month high of $19.62.

Pliant Therapeutics Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.